T Progenitor and Thymic Epithelial Cell Replacement Post Transplant
T Progenitor and Thymic Epithelial Cell Replacement Post Transplant
批准号:
8310801
负责人:
Bruce R Blazar
金额:
$34.28万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-08-01 至 2015-06-30
关键词:
Adenovirus InfectionsAdultAffectAgeBiologyBypassCell Differentiation processCell TransplantsCell physiologyCellsCuesCytomegalovirusCytotoxic ChemotherapyDataDefectDevelopmentDiGeorge SyndromeDiseaseDoseEndoderm CellEpithelial Cell ProliferationGenerationsGenesGenetic TranscriptionGoalsHalf-LifeHematopoieticHomingHuman Herpesvirus 6IL7 geneImageImmuneIncidenceInfectionInjuryInterleukin-7LigandsMalignant - descriptorMature T-LymphocyteMature ThymocyteMediatingMethodologyMinorityMorbidity - disease rateMusNatural regenerationNon-MalignantPatientsPatternPhotonsPluripotent Stem CellsPredispositionProcessRecoveryRecovery of FunctionRegimenRelative (related person)Residual stateRodentSignal TransductionSiteSourceStagingStem cellsSystemT-LymphocyteTNFSF11 geneTechnologyTestingThymic epithelial cellThymocyte SelectionThymus GlandTransplant RecipientsTransplantationUmbilical Cord Bloodagedbasebone morphogenic proteinclinically relevantclinically significantconditioningcytotoxicgraft vs host diseasehuman stem cellsimpaired capacityin vivoinduced pluripotent stem cellinjuredkeratinocyte growth factormigrationmortalitynotch proteinnovelpathogenpreventprogenitorprotein complexreceptorreconstitutionstemstem cell technologythymocytetumorviral DNA
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Immune deficiency causes significant morbidity and mortality in hematopoietic cell transplant (HCT) recipients. The clinical significance is especially evident when utilizing high doses of cytotoxic conditioning, donor HSC sources that are HLA-mismatched or contain low numbers of mature T lymphocytes, as would be the case with umbilical cord blood (UCB) transplants. We have observed a high incidence of severe or fatal intracellular and DNA viral (CMV; EBV; HHV6; adenovirus) infections in UCB transplant recipients. A major cause is loss of thymopoietic capacity, and impaired T cell recovery as a result of age, chemoradiotherapy or graft-versus-host-disease. Thymopoiesis depends on the interaction of the thymic stroma-derived receptors and ligands. Damage to thymic epithelial cells (TECs) by pre-transplant conditioning impairs the generation of mature T cells following transplant and predisposes the recipient to infections. Our central hypothesis is that thymic microenvironmental injury is the major limiting factor for
slow T cell reconstitution and function in UCB transplant recipients, indicated by the predisposition for late infections. TEC differentiation, proliferation, and survival are controlled by both cell intrinsic and extrinsic factors. Thymocyte precursors and TECs engage in "cross-talk" such that bidirectional signaling mechanisms provided by and to both thymocytes and TECs are essential for their mutual proliferation and survival. Our preliminary data in mice indicate that there is a direct correlation between the number of mature thymocytes and TECs, especially those located in the thymic medulla, which serves as the primary site of negative selection and thymic egress into the periphery.
With the operational hypothesis that the rapidity of recovery of effective thymopoiesis is limited both by ineffective :TEC cross-talk (aim 1) and the relative paucity of endogenous TECs that escape conditioning regimens (aims 1, 2). We will pursue two approaches (specific aims) to overcome the quantitative and qualitative defect in TEC support of thymopoiesis. Aim 1. To determine whether TEC regeneration and thymopoietic recovery is limited by inadequate cross-talk between thymocyte precursors and TECs post-HSCT. Aim 2. To devise and test novel TEC replacement strategies based upon TEC developmental cues and using inducible pluripotent stem cell technology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)
-
批准号:10763967
-
项目类别:
-
资助金额:$772.72万
-
财政年份:2023
-
负责人:Bruce R Blazar
-
依托单位:
In Vivo Prevention of Murine GVHD
-
批准号:10362877
-
项目类别:
-
资助金额:$60.35万
-
财政年份:2022
-
负责人:Bruce R Blazar
-
依托单位:
Metabolomics of cGVHD
-
批准号:10698171
-
项目类别:
-
资助金额:$56.98万
-
财政年份:2022
-
负责人:Bruce R Blazar
-
依托单位:
In Vivo Prevention of Murine GVHD
-
批准号:10610863
-
项目类别:
-
资助金额:$58.97万
-
财政年份:2022
-
负责人:Bruce R Blazar
-
依托单位:
Metabolomics of cGVHD
-
批准号:10493800
-
项目类别:
-
资助金额:$59.42万
-
财政年份:2022
-
负责人:Bruce R Blazar
-
依托单位:
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
-
批准号:10092348
-
项目类别:
-
资助金额:$67.52万
-
财政年份:2021
-
负责人:Bruce R Blazar
-
依托单位:
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
-
批准号:10560605
-
项目类别:
-
资助金额:$66.97万
-
财政年份:2021
-
负责人:Bruce R Blazar
-
依托单位:
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
-
批准号:10348683
-
项目类别:
-
资助金额:$66.24万
-
财政年份:2021
-
负责人:Bruce R Blazar
-
依托单位:
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia
-
批准号:10305635
-
项目类别:
-
资助金额:$6.75万
-
财政年份:2019
-
负责人:Bruce R Blazar
-
依托单位:
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia
-
批准号:10656502
-
项目类别:
-
资助金额:$81.18万
-
财政年份:2019
-
负责人:Bruce R Blazar
-
依托单位:
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia
-
批准号:9888096
-
项目类别:
-
资助金额:$84.95万
-
财政年份:2019
-
负责人:Bruce R Blazar
-
依托单位:
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia
-
批准号:10532723
-
项目类别:
-
资助金额:$75.14万
-
财政年份:2019
-
负责人:Bruce R Blazar
-
依托单位:
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)
-
批准号:9901640
-
项目类别:
-
资助金额:$697.02万
-
财政年份:2018
-
负责人:Bruce R Blazar
-
依托单位:
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)
-
批准号:10366062
-
项目类别:
-
资助金额:$577.8万
-
财政年份:2018
-
负责人:Bruce R Blazar
-
依托单位:
Preclinical Drug Approaches to Chronic GVHD Prevention and Treatment
-
批准号:8881478
-
项目类别:
-
资助金额:$20.95万
-
财政年份:2015
-
负责人:Bruce R Blazar
-
依托单位:
Enhancing Treg Therapeutic Efficacy in GVHD
-
批准号:8837683
-
项目类别:
-
资助金额:$42.35万
-
财政年份:2014
-
负责人:Bruce R Blazar
-
依托单位:
Mechanisms, Prevention and Treatment of Chronic GVHD
-
批准号:8746996
-
项目类别:
-
资助金额:$62.81万
-
财政年份:2014
-
负责人:Bruce R Blazar
-
依托单位:
Enhancing Treg Therapeutic Efficacy in GVHD
-
批准号:10616775
-
项目类别:
-
资助金额:$69.68万
-
财政年份:2014
-
负责人:Bruce R Blazar
-
依托单位:
Enhancing Treg Therapeutic Efficacy in GVHD
-
批准号:10452167
-
项目类别:
-
资助金额:$72.25万
-
财政年份:2014
-
负责人:Bruce R Blazar
-
依托单位:
Enhancing Treg Therapeutic Efficacy in GVHD
-
批准号:8690244
-
项目类别:
-
资助金额:$44.3万
-
财政年份:2014
-
负责人:Bruce R Blazar
-
依托单位:
海外基金